Colon Bacteria Can Trigger GLP-1 Release. Here’s the Receptor Mechanism Behind It.

Injected GLP-1 drugs have reshaped how clinicians treat type 2 diabetes and obesity, but they require lifelong administration and carry significant costs. A different approach, coaxing the gut's own hormone-secreting cells to release more GLP-1 naturally, has attracted growing scientific interest. Early research now identifies two receptors, FFAR2 and FFAR3, as key gatekeepers linking bacterial metabolites in the colon to GLP-1 output, with FFAR2 playing the dominant role.

FFAR2 Receptor Controls SCFA-Triggered GLP-1 Secretion in L Cells

The study, published in Diabetes, focused on intestinal L cells, the specialized enteroendocrine cells diffusely scattered through the gut lining that produce GLP-1 and the appetite-suppressing peptide PYY. Researchers used a transgenic mouse model called GLU-Venus, which tags L cells with a fluorescent marker, to isolate these cells and study them directly. What they found was that short-chain fatty acids (SCFAs), molecules produced when gut bacteria ferment dietary fiber, triggered calcium signals specifically inside L cells but not in neighboring non-L cells. That selectivity pointed immediately to receptor-level specificity.

SCFAs include acetate (roughly 60% of colonic SCFAs), propionate (about 25%), and butyrate (about 15%), and they reach concentrations as high as 100 mmol/L in the colon. Both acetate and propionate at 1 mmol/L significantly stimulated GLP-1 secretion from primary murine colonic cultures. The receptors FFAR2 (also called GPR43) and FFAR3 (GPR41) were found to be significantly enriched in L cells compared to surrounding cells, and a FFAR2-specific agonist called CFMB elevated intracellular calcium in L cells at 30 micromoles per liter, providing direct pharmacological confirmation.

Research from the Akkermansia muciniphila and GLP-1 secretion literature has similarly highlighted how specific bacterial species and their secreted proteins can stimulate L-cell hormone output, reinforcing the broader hypothesis that the gut microbiome is an active regulator of metabolic hormone secretion rather than a passive bystander.

What Reduced GLP-1 Means for Glucose Tolerance and Insulin

To confirm that FFAR2 and FFAR3 are not just associated with GLP-1 release but actually required for it, the team generated mice with targeted knockouts of each receptor gene. The results were striking. Knocking out ffar2 abolished the GLP-1 secretion response to acetate entirely and reduced the propionate response by 70%. Knocking out ffar3 also impaired SCFA-triggered GLP-1 release, though less severely. Both knockout strains showed reduced basal and glucose-stimulated plasma GLP-1 levels in vivo.

Those hormonal deficits translated into metabolic consequences. Both ffar2-deficient and ffar3-deficient mice exhibited impaired glucose tolerance and reduced plasma insulin levels after an oral glucose load. Importantly, insulin tolerance tests showed no difference in insulin sensitivity, meaning the glucose tolerance impairment traced to insufficient insulin secretion, not resistance. That mechanistic chain, from absent SCFA receptor signaling to lower GLP-1 to blunted insulin release to worse glucose handling, builds a compelling physiological case for the receptor pathway's importance.

These findings matter because GLP-1 receptor agonists have already demonstrated consistent benefits for blood glucose control, weight reduction, and cardiovascular outcomes in large clinical trials. A strategy that amplifies endogenous GLP-1 production through FFAR2 could theoretically complement or, in milder cases, substitute for pharmacological agonists.

How the GLU-Venus Mouse Model Made L-Cell Isolation Possible

A key methodological challenge in L-cell research is that these cells make up less than 1% of intestinal epithelial cells. The GLU-Venus transgenic model solved this by driving Venus fluorescent protein expression under the proglucagon promoter, allowing FACS-based sorting to separate L cells from the surrounding epithelium with high purity. Quantitative RT-PCR on sorted populations confirmed that ffar2 and ffar3 mRNA were significantly enriched in L cells, not just expressed at low levels throughout the gut wall.

Calcium imaging with Fura2-AM dye provided real-time readouts of cellular activation. The cell-specific calcium responses to SCFAs, present in Venus-positive L cells and absent in Venus-negative neighbors, established that the signaling was not a diffuse epithelial effect but genuinely L-cell-selective. The team also used pertussis toxin to probe Gi-coupled signaling and found that acute SCFA-induced GLP-1 secretion was not mediated through the Gi pathway, pointing instead to Gq-coupled calcium mobilization as the primary acute mechanism for FFAR2.

Separately, tributyrin supplementation research using CoreBiome has shown that raising butyrate availability in the gut can simultaneously increase Akkermansia muciniphila abundance and modulate intestinal barrier function, suggesting that nutritional strategies to shift the SCFA landscape could have layered effects on L-cell stimulation.

Open Questions About Receptor Localization and Metabolic Disease Context

The study's authors are careful about what they cannot yet conclude. It remains unclear whether the reduced plasma GLP-1 levels in ffar2-deficient mice reflect impaired secretion, reduced colonic GLP-1 protein content, or a combination of both. The knockout mice also showed lower ffar3 expression alongside ffar2 deletion, raising the possibility that some of the observed phenotype reflects secondary loss of ffar3 tone rather than ffar2 alone.

Perhaps more consequentially for translation, neither the apical nor the basolateral surface localization of FFAR2 and FFAR3 on L cells has been established. That distinction matters: luminal SCFAs at high colonic concentrations would only reach apically-facing receptors, while circulating plasma SCFAs at 100 to 200 micromoles per liter would reach basolateral receptors. Both routes may operate, but the balance shapes how dietary fiber and microbiome composition influence L-cell function in practice.

A recent review on microbiome influence on GLP-1 drug response makes the broader point that microbial metabolites likely regulate endogenous GLP-1 in ways that could affect how patients respond to GLP-1 receptor agonist drugs, but that human mechanistic research is still in early stages. Whether the FFAR2 pathway is altered in people with type 2 diabetes or obesity, where gut microbiome composition is known to differ, remains an open question.

FFAR2 as a Pharmacological Target for Enteroendocrine Stimulation

The study's authors propose that FFAR2 should be considered a serious pharmacological target for stimulating the enteroendocrine system. A selective oral FFAR2 agonist could, in principle, amplify GLP-1 output from colonic L cells without the injection burden of current GLP-1 mimetics. The finding that circulating plasma SCFA concentrations of 100 to 200 micromoles per liter fall within the receptor's working range hints that systemic delivery of SCFA analogs might be enough to engage basolateral FFAR2, bypassing the challenge of delivering drugs to the colon intact.

This is early-stage, investigational research conducted in mice, and translating receptor biology from murine models to human metabolic disease carries well-known hurdles. But the specificity of the L-cell calcium response, the magnitude of the knockout phenotypes, and the direct chain from receptor activation to improved glucose tolerance give this receptor a cleaner mechanistic story than many candidate targets at comparable stages.

Evidence rating

INVESTIGATIONAL — 75/100

Caveats:

• All mechanistic experiments were conducted in mice, not humans — findings may not translate directly to human physiology.
• In vitro cultures and knockout mouse models cannot fully replicate the complexity of the living gut environment.
• Glucose tolerance impairment in knockout mice may reflect roles of FFAR2/FFAR3 outside the gut (e.g., immune cells, adipocytes, pancreatic beta cells), not GLP-1 effects alone.
• Funding source was not disclosed by the authors.

Preclinical study combining primary murine colonic cultures, calcium imaging, FACS-sorted L cells, and two receptor-specific knockout mouse lines (ffar2−/− and ffar3−/−). Demonstrates a step-by-step mechanistic link from SCFA exposure to FFAR2 activation, intracellular calcium elevation, and GLP-1 secretion, with in vivo confirmation via impaired glucose tolerance in knockout animals. All data are animal-derived; no human subjects were included, so direct clinical translation remains unestablished. Findings are consistent with prior immunohistochemical reports of FFAR2/FFAR3 expression in human colonic L cells but have not been independently replicated in a human intervention trial.

References

1. Gwen Tolhurst, Helen Heffron, Yu Shan Lam, et al. (2012). Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2. Diabetes. https://doi.org/10.2337/db11-1019
2. Ananta Prasad Arukha, Subhendu Nayak, Durga Madhab Swain (2025). Effect of Akkermansia muciniphila on Glp and Insulin Secretion. https://doi.org/10.20944/preprints202506.0300.v1
3. Ushna Gul, Thandar Aung, Mehwish Martin, et al. (2024). A Comprehensive Review of the Role of GLP-1 Agonists in Weight Management and Their Effect on Metabolic Parameters Such as Blood Glucose, Cholesterol, and Blood Pressure. Cureus. https://doi.org/10.7759/cureus.76519
4. Cindy Duysburgh, Lynn Verstrepen, Lieven Van Meulebroek, Massimo Marzorati (2025). Tributyrin (CoreBiome®) enhances butyrate levels and modulates the gut microbiota, barrier function, and immune response in vitro. Frontiers in Nutrition. https://doi.org/10.3389/fnut.2025.1712993
5. (2025). Issue Information. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.16104